XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Breast Cancer
Interventions: DRUG: capecitabine|DRUG: docetaxel
Sponsor: Hoffmann-La Roche